[1] Zhu C, Xiao F, Lin W. EFTUD2 on innate immunity. Oncotarget, 2015, 6(32):32313-32314. [2] Zhu C, Xiao F, Hong J, et al. EFTUD2 is a novel innate immune regulator restricting hepatitis C virus infection through the RIG-I/MDA5 pathway. J Virol, 2015, 89(13):6608-6618. [3] Lyu Z, Wang Z, Luo L, et al. Spliceosome protein EFTUD2 promotes colitis-associated tumorigenesis by modulating inflammatory response of macrophage. Mucosal Immunol, 2019, 12(5):1164-1173. [4] Tu M, He L, You Y, et al. EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3. Cell Death Dis, 2020, 11(10):830. [5] Lei L, Yan SY, Yang R, et al. Spliceosomal protein EFTUD2 mutation leads to p53-dependent apoptosis in zebrafish neural progenitors. Nucleic Acids Res, 2017, 45(6):3422-3436. [6] Wu J, Yang Y, He Y, et al. EFTUD2 gene deficiency disrupts osteoblast maturation and inhibits chondrocyte differentiation via activation of the p53 signaling pathway. Hum Genomics, 2019, 13(1):63. [7] Huang L, Vanstone MR, Hartley T, et al. Mandibulofacial dysostosis with microcephaly: mutation and database update. Hum Mutat, 2016, 37(2):148-154. [8] Lehalle D, Wieczorek D, Zechi-Ceide RM, et al. A review of craniofacial disorders caused by spliceosomal defects. Clin Genet, 2015, 88(5):405-415. [9] Tang L, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA, 2018, 319(17):1802-1813. [10] Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers, 2018, 4:18035. [11] Dusheiko G. Will we need novel combinations to cure HBV infection? Liver Int, 2020, 40(Suppl 1):35-42. [12] Petersen J, Thompson A J, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol, 2016, 65(4):835-848. [13] Pierra RC, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res, 2020, 179:104815. [14] Vigano M, Grossi G, Loglio A, et al. Treatment of hepatitis B: is there still a role for interferon? Liver Int, 2018, 38(Suppl 1):79-83. [15] Fabrizio P, Laggerbauer B, Lauber J, et al. An evolutionarily conserved U5 snRNP-specific protein is a GTP-binding factor closely related to the ribosomal translocase EF-2. EMBO J, 1997, 16(13):4092-4106. [16] Frazer LN, Nancollis V, O'Keefe RT. The role of Snu114p during pre-mRNA splicing. Biochem Soc Trans, 2008, 36(Pt 3):551-553. [17] Bartels C, Urlaub H, Luhrmann R, et al. Mutagenesis suggests several roles of Snu114p in pre-mRNA splicing. J Biol Chem, 2003, 278(30):28324-28334. [18] Hayes CN, Chayama K. HBV culture and infectious systems. Hepatol Int, 2016, 10(4):559-566. [19] Torresi J, Tran BM, Christiansen D, et al. HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models. BMC Cancer, 2019, 19(1):707. [20] Li F, Wang Z, Hu F, et al. Cell culture models and animal models for HBV study. Adv Exp Med Biol, 2020, 1179:109-135. |